26 February 2024 MAYNE PHARMA REPORTS 1H FY24 RESULTS WITH A 43% INCREASE IN REVENUE TO A$188 MILLION AND $8 MILLION UNDERLYING EBITDA 0 minute read Pharma/Biotech By Cate Swannell Previous Post Next Post